Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 355.89M P/E - EPS this Y 43.20% Ern Qtrly Grth -
Income -29.25M Forward P/E - EPS next Y -135.10% 50D Avg Chg 1.00%
Sales 2M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -3.00%
Recommedations 2.00 Quick Ratio 29.05 Shares Outstanding 30.67M 52W Low Chg 9.00%
Insider Own 14.11% ROA -21.54% Shares Float 16.20M Beta -
Inst Own 70.10% ROE -29.32% Shares Shorted/Prior 2.07M/1.81M Price 16.05
Gross Margin 100.00% Profit Margin - Avg. Volume 89,276 Target Price 32.60
Oper. Margin -1,813.75% Earnings Date - Volume 57,395 Change 0.25%
About Sagimet Biosciences Inc. - Seri

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc. - Seri News
11/18/24 Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
11/18/24 Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
11/14/24 Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
11/07/24 Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
10/29/24 Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
10/16/24 Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
10/11/24 Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
10/01/24 Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
09/30/24 Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/12/24 Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
09/04/24 Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
08/14/24 Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
08/01/24 Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
06/21/24 Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
06/10/24 Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
06/06/24 Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
05/16/24 Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
05/15/24 Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
05/07/24 Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
05/06/24 Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
SGMT Chatroom

User Image valueforme Posted - 2 hours ago

$SGMT https://www.biotechtv.com/post/sagimet-biosciences-november-19-2024

User Image Dark_Horse_Investments Posted - 1 day ago

What is your point? your coarse statement below is devoid of fundamental reasoning - just being transparent. My applause to you for being a medical doctor. My sincere thanks. But how does this qualify you in any shape or form when it comes to funding a capital structure of an emerging biotech ie $SGMT ? I mean that is unless you are an advisor investor to a science fund (as I have) and have done capital finance rounds multiple times. So please share with us, perhaps your material is worth reviewing... Thanks in advance

User Image Dark_Horse_Investments Posted - 1 day ago

$SGMT good lively exchanges, thx Maybe it is as you say (well, as they say - non dilutive financing ). As a capital structure guy, I would be very concerned if a sub $200 million capitalization company raises $300 or more million in debt. Perhaps I am skeptic or we are all naïve in believing that they will get free cash. But strange are the roads that lead to success... I do expect some kind of a PIPE deal ( private investment in public equity ) accompanied by leverage... I have underwritten said investments in the past. Lets see - I like the science and as I said this thing will be approved and accrete value for patient investors...

User Image nastento Posted - 1 day ago

$SGMT seems to be pinned at 4.50...maybe I am wrong about financing

User Image Dark_Horse_Investments Posted - 2 days ago

$SGMT @idousky If your holdings in SGMT is a significant bulk of your portfolio and you’re experiencing a major loss (eg purchased in January), maybe a sell is for you. I’m conducting due diligence and currently own a small amount but plan to buy more. my portfolio is small relative to others but for context I am targeting to add on the drawdown about $20-$30k worth of shares. The main challenge isn't product approval but raising $200-$300 million for phase 3 trials. The compound is unique, which aligns with our strategy. The market segment has strong competition (e.g., $AKRO, $MDGL), but our unique inhibitor has potential. I don’t see $VKTX-2809 as a relevant competitor.

User Image idousky Posted - 2 days ago

$SGMT thinking about selling all my shares , any second thoughts?

User Image kthart Posted - 2 days ago

$SGMT whelp, patience and a little trading should pay off here. Loaded with 50% more shares than I had during the first run-up, at the same cost. It wasn't easy buying below $3 but I'm better for it!

User Image valueforme Posted - 2 days ago

$SGMT An example of selling royalties on phase 3 ready asset https://ir.sutrobio.com/news-events/news-releases/detail/176/sutro-biopharma-and-blackstone-announce-royalty-financing-collaboration

User Image smolcapcat Posted - 3 days ago

$SGMT I'm in, bonjour

User Image Peterson28 Posted - 3 days ago

$SGMT Calm down rookie. Barely 200 shares traded. It will come back down 15% after market open.

User Image whiskas007 Posted - 3 days ago

$SGMT up 15ء%… any news ?

User Image cats44ever Posted - 4 days ago

$SGMT Have to assume the only viable time to announce a deal before year end (as SGMT stated they want financing for PH3 resolved before starting trials), is this week and the first 3 weeks in December. Can't see a Thanksgiving week deal & as Christmas & New Years are on Wednesdays this year, I don't see a deal on those weeks...and therefore, can't see a deal after the 20th of December. So...It seems that the December options market (ending 12/20) is predicting that there will be minimal stock-price movement to the upside from here. Dec 5 calls are 30 cent bid 40 cent offer. Not trying to be negative here; just realistic. April 7 1/2 & July 10 calls suggest decent appreciation opportunities.

User Image Effe839 Posted - 4 days ago

$SGMT Crazy how static it has been since 11.40 AM

User Image nastento Posted - 4 days ago

$SGMT flushing out before news?

User Image cats44ever Posted - 5 days ago

$SGMT 2 cents on what's going on... It's possible that big pharma is concerned with the hair loss/hair thinning side effect. Seems that every recent conference/presentation... the hosting analyst presses Happel & Martins for answers to this Adverse Event. Happel responded (a few months ago... I don't remember which conference) that there had been no hair loss AE's in the Chinese Acne trial to date... unfortunately, the trial results have been pushed back 3 months. For the patient investors... if... the Acne trial (which should have interim topline data May-2025, is positive... AND... there is no hair loss side effect... SGMT goes to at least $12.

User Image nastento Posted - 5 days ago

$SGMT 100% chance of non dilutive financing

User Image nastento Posted - 5 days ago

$SGMT sure would be nice to release that financing news to stop the bleeding...

User Image Stokwits Posted - 5 days ago

$SGMT buying more tomorrow morning

User Image GXD_Texas Posted - 5 days ago

$SGMT yay. I’m just living my best life”Brat” life lol.

User Image Effe839 Posted - 5 days ago

$SGMT About to buy some more at 4,20€ That number is not random 👀

User Image Expharmaguy Posted - 5 days ago

$SGMT Sell off is not surprising. Wall St is waiting for the company to report that they have enough cash to initiate their 2 Phase 3 trials in MAFLD and MASH. While the AI presented today is interesting, we have known the general result of their phase 2 for a while now, so its nothing that new, just a very granular look at some of the patients. Study published in the Lancet, but w/o the AI info. We need to start these Phase 3 trials.

User Image Jabed206 Posted - 5 days ago

$SGMT Keeps on dropping, down to $2.50 probably lol

User Image Expharmaguy Posted - 5 days ago

$SGMT Good article on SGMT on Seeking Alpha that focused mainly on their drug's potential in Acne Vulgaris

User Image Stokwits Posted - 5 days ago

$SGMT 😲

User Image Jabed206 Posted - 5 days ago

$SGMT oh, great sell off

User Image Jabed206 Posted - 5 days ago

$SGMT https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-presents-clinical-denifanstat-and

User Image Jabed206 Posted - 5 days ago

$SGMT https://www.stocktitan.net/news/SGMT/sagimet-biosciences-presents-clinical-denifanstat-and-preclinical-o5re91rcrkj6.html

User Image Jabed206 Posted - 5 days ago

$SGMT been buying and averaging down

User Image yukselkaradeniz Posted - 5 days ago

$SGMT added more

User Image valueforme Posted - 5 days ago

$SGMT I keep buying as it will be too late after this

Analyst Ratings
HC Wainwright & Co. Buy Oct 2, 24
JMP Securities Market Outperform Aug 15, 24
HC Wainwright & Co. Buy Aug 15, 24
Goldman Sachs Neutral Jul 1, 24
HC Wainwright & Co. Buy Jun 14, 24
JMP Securities Market Outperform Jun 7, 24
HC Wainwright & Co. Buy Jun 7, 24
JMP Securities Market Outperform May 24, 24
HC Wainwright & Co. Buy May 24, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Happel David President & CEO President & CEO Nov 16 Buy 2.35 590 1,386 590 11/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Sell 16 662 10,592 3,820,275 07/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Buy 16 30,000 480,000 3,850,275 07/20/23